Drug-related expenses for first-line treatment in advanced stage classic Hodgkin lymphoma
| First-line regimen (dose) . | Drug expenses per cycle, USD* . |
|---|---|
| ABVD | 277.17 |
| Doxorubicin (25 mg/m2, days 1 and 15) | 31.01 |
| Bleomycin (10 IU/m2, days 1 and 15) | 98.75 |
| Vinblastine (6 mg/m2, days 1 and 15) | 78.72 |
| Dacarbazine (375 mg/m2, days 1 and 15) | 68.69 |
| Escalated BEACOPP | 4445.21 |
| Doxorubicin (35 mg/m2, day 1) | 18.61 |
| Cyclophosphamide (1250 mg/m2, day 1) | 936.35 |
| Etoposide (200 mg/m2, days 1-3) | 25.19 |
| Procarbazine (100 mg/m2, days 1-7) | 2204 |
| Prednisone (40 mg/m2, days 1−14) | 11 |
| Bleomycin (10 IU/m2, day 8) | 49.37 |
| Vincristine (2 mg, day 8) | 9.99 |
| Filgrastim, biosimilar (300 μg, days 9-15) | 1190.70 |
| BV + AVD | 33 834.42 |
| Brentuximab vedotin (1.2 mg/m2, days 1 and 15) | 31 274.60 |
| Doxorubicin (25 mg/m2, days 1 and 15) | 31.01 |
| Vinblastine (6 mg/m2, days 1 and 15) | 78.72 |
| Dacarbazine (375 mg/m2, days 1 and 15) | 68.69 |
| Filgrastim, biosimilar (300 μg, days 3-9 and 18-24) | 2381.40 |
| First-line regimen (dose) . | Drug expenses per cycle, USD* . |
|---|---|
| ABVD | 277.17 |
| Doxorubicin (25 mg/m2, days 1 and 15) | 31.01 |
| Bleomycin (10 IU/m2, days 1 and 15) | 98.75 |
| Vinblastine (6 mg/m2, days 1 and 15) | 78.72 |
| Dacarbazine (375 mg/m2, days 1 and 15) | 68.69 |
| Escalated BEACOPP | 4445.21 |
| Doxorubicin (35 mg/m2, day 1) | 18.61 |
| Cyclophosphamide (1250 mg/m2, day 1) | 936.35 |
| Etoposide (200 mg/m2, days 1-3) | 25.19 |
| Procarbazine (100 mg/m2, days 1-7) | 2204 |
| Prednisone (40 mg/m2, days 1−14) | 11 |
| Bleomycin (10 IU/m2, day 8) | 49.37 |
| Vincristine (2 mg, day 8) | 9.99 |
| Filgrastim, biosimilar (300 μg, days 9-15) | 1190.70 |
| BV + AVD | 33 834.42 |
| Brentuximab vedotin (1.2 mg/m2, days 1 and 15) | 31 274.60 |
| Doxorubicin (25 mg/m2, days 1 and 15) | 31.01 |
| Vinblastine (6 mg/m2, days 1 and 15) | 78.72 |
| Dacarbazine (375 mg/m2, days 1 and 15) | 68.69 |
| Filgrastim, biosimilar (300 μg, days 3-9 and 18-24) | 2381.40 |
ABVD, doxorubicin, bleomycin, vinblastine, dacarbazine; AVD, doxorubicin, vinblastine, decarbazine; BEACOPP, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone; BV, brentuximab vedotin.
Drug expenses based on Medicare’s published average sales price (April 2019) and incorporate drug wastage related to single-use vial size. Expenses are calculated for a 75-kg patient whose height is 1.7 m2.